Investing in MedTech Innovation That Elevates Care — and Generates Returns
MedTech is Central to Healthcare’s Transformation
The pace and scope of Innovation is reshaping the care continuum, expanding access, and redefining clinical practice. The convergence of software, hardware, biology, and AI is enabling scalable, integrated platforms with data, services, and clinical intelligence layers. As innovation and capital increasingly align, a durable opportunity has emerged for specialized investors with deep sector fluency and disciplined underwriting.
We are here to support that evolution — with focus, expertise, and alignment.
About Us
INAYA Capital is a Venture Capital Firm With a Singular Focus on the MedTech Sector
[ ihː na: ya ] : (care, concern, blessing, solicitude)We partner with exceptional innovators to build high-impact medical technologies with durable clinical relevance and clear economic value.
Our investments span medical devices, tools & diagnostics, and digital health, with emphasis on therapeutic areas where human burden is significant and rising.
Our investment approach is stage-agnostic, with an early-entry bias (Seed to Series B) where engagement can shape long-term value creation.
We combine disciplined capital deployment with founder alignment and a structure designed to deliver superior returns for all stakeholders.
We recognize two persistent structural gaps in MedTech: capital formation and ecosystem depth. Through specialized capital and active ecosystem engagement, we help bridge both.
Investing Where Innovation is Necessary, Adoptable, Scalable
Our underwriting is grounded in a consistent and disciplined framework, with emphasis on clear problem–solution alignment, defensible science, and a defined path to clinical validation. Opportunities are assessed for early visibility into reimbursement logic, adoption dynamics, and sustainable economics.
The objective is to back technologies capable of delivering meaningful patient impact with realistic system integration and multiple credible exit pathways.
Proprietary Origination and Cofounding
Alongside traditional deal flow, we originate opportunities we know deeply and selectively build companies from inception. Our model is informed by direct experience investing alongside leading U.S. MedTech innovation platforms.
We engage early — at the problem-definition stage — often before company formation. Opportunities emerge from proprietary internal insights and trusted external partners. We rigorously assess technical feasibility, clinical relevance, regulatory pathways, capital efficiency, and value-creation potential to shape executable plans. We advance only those opportunities aligned with disciplined underwriting and fund objectives.
Where appropriate, we take an active role — leveraging our industry access, strategic guidance, and operating insight to accelerate development and strengthen long-term positioning.
Our objective is to create disproportionate value for our stakeholders through earlier, differentiated engagement and thoughtful partnership
Our Investments
We have backed transformative MedTech advancements — from seed-stage innovation to late-stage category leaders.
ACTIVE
ACTIVE
ACTIVE
Acquired by JNJ
Acquired by Boston Scientific
Acquired by Boston Scientific
Acquired by Abbott
Acquired by Covidien
Acquired by Imperative Care
Acquired by Nikkiso
The portfolio companies listed above represent investments sourced, monitored or exited by the General Partner at INAYA Capital and / or the predecessor firm(s).INAYA Team
We bring decades of diverse and complementary global MedTech expertise — spanning clinical, operations, & finance — to every company we back.
Ashkan Haghighat, PhD
General Partner
Guy Leclerc, MD
Inter. Cardiologist
CEO/Founder Accelab
Advisor
William Hunter, MD
CEO, Canary Medical
CEO, Angiotech
Advisor
Amr Salahieh
CEO, Shifamed LLC
Advisor
Lori Chmura
CEO, Nyra Medical
JNJ, Medtronic
Advisor